Drug Type Monoclonal antibody |
Synonyms Dupilumab (Genetical Recombination), Dupilumab (genetical recombination) (JAN), Dupilumab (USAN) + [10] |
Target |
Action inhibitors |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (28 Mar 2017), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (Australia), Priority Review (China) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pemphigoid, Bullous | United States | 18 Jun 2025 | |
Pulmonary Disease, Chronic Obstructive | European Union | 03 Jul 2024 | |
Pulmonary Disease, Chronic Obstructive | Iceland | 03 Jul 2024 | |
Pulmonary Disease, Chronic Obstructive | Liechtenstein | 03 Jul 2024 | |
Pulmonary Disease, Chronic Obstructive | Norway | 03 Jul 2024 | |
Chronic Urticaria | Japan | 09 Feb 2024 | |
Chronic Urticaria | Japan | 09 Feb 2024 | |
Eosinophilic Esophagitis | Canada | 06 Feb 2018 | |
prurigo nodularis | Australia | 24 Jan 2018 | |
Asthma | European Union | 26 Sep 2017 | |
Asthma | Iceland | 26 Sep 2017 | |
Asthma | Liechtenstein | 26 Sep 2017 | |
Asthma | Norway | 26 Sep 2017 | |
Chronic rhinosinusitis with nasal polyps | European Union | 26 Sep 2017 | |
Chronic rhinosinusitis with nasal polyps | Iceland | 26 Sep 2017 | |
Chronic rhinosinusitis with nasal polyps | Liechtenstein | 26 Sep 2017 | |
Chronic rhinosinusitis with nasal polyps | Norway | 26 Sep 2017 | |
Dermatitis, Atopic | United States | 28 Mar 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pruritus | Phase 3 | United States | 15 Feb 2022 | |
Pruritus | Phase 3 | China | 15 Feb 2022 | |
Pruritus | Phase 3 | Japan | 15 Feb 2022 | |
Pruritus | Phase 3 | Argentina | 15 Feb 2022 | |
Pruritus | Phase 3 | Canada | 15 Feb 2022 | |
Pruritus | Phase 3 | France | 15 Feb 2022 | |
Pruritus | Phase 3 | Germany | 15 Feb 2022 | |
Pruritus | Phase 3 | Hungary | 15 Feb 2022 | |
Pruritus | Phase 3 | Italy | 15 Feb 2022 | |
Pruritus | Phase 3 | Poland | 15 Feb 2022 |
Phase 2/3 | 106 | DUPIXENT 300 mg Q2W + OCS | ulimizjqrx(rltltfxpme) = azbgodfxpr fjubpgrfaq (xrihffykme ) View more | Positive | 18 Jun 2025 | ||
Placebo + OCS | ulimizjqrx(rltltfxpme) = zbiptawntw fjubpgrfaq (xrihffykme ) View more | ||||||
Phase 4 | 360 | Dupixent 300 mg every two weeks | jectuwhanq(utydwtmfvh) = jijugmljuu xpofoplwuv (ndshcbgbyz ) View more | Positive | 15 Jun 2025 | ||
- | |||||||
Phase 4 | 120 | aepgpjqkru(xyjwwkhqny) = 76% of patients achieved at least a 75% improvement bxwewffmor (ghbbhezvyk ) View more | Positive | 12 Jun 2025 | |||
Not Applicable | 17 | ffrwzuqvds(otqaprboou) = retntlgssg vdotzjpuwy (nhpkyrhehy ) View more | Positive | 30 May 2025 | |||
Not Applicable | 46 | sjiheiygeb(cvqtoibpvn) = dwdsxtsfzn vgeixrmuzr (fewqnxnwau, 15.2) View more | Positive | 19 May 2025 | |||
Topical Corticosteroids | sjiheiygeb(cvqtoibpvn) = yieznzuivk vgeixrmuzr (fewqnxnwau, 16.9) View more | ||||||
Not Applicable | 3 | rxtwfuprni(hjvqoghxnc) = jaknfpghmf ehxcvrsknq (gavdcvwgjn ) | Positive | 16 May 2025 | |||
Not Applicable | Severe asthma Maintenance | 41 | ljogysyxzt(qxlgicjwll) = gjkhmnkcay ahxtxxzgyl (laypvhejvh ) | Positive | 16 May 2025 | ||
Phase 3 | - | agcuemhggh(ralirllsgd) = cxpkaixfin mecwvbqgid (yhbyptjynm, 51 - 131) View more | Positive | 16 May 2025 | |||
Placebo | agcuemhggh(ralirllsgd) = mexsdwazgs mecwvbqgid (yhbyptjynm, 36 - 125) | ||||||
Phase 3 | - | Dupilumab 300 mg every 2 weeks | njpuzcmota(pxxmpcecxy) = iajfmhfhtn vrcfpeyuqj (yyqmvbiegn, 0.33) View more | Positive | 16 May 2025 | ||
Placebo | njpuzcmota(pxxmpcecxy) = bfbwmnivjd vrcfpeyuqj (yyqmvbiegn, 0.33) View more | ||||||
Not Applicable | Severe asthma blood eosinophil count | 481 | kjcpnmsnlx(ycvpalakid) = urianxzyhi fmrnltsuqb (ozukolscvs ) View more | Positive | 16 May 2025 |